(3S,5S,6R)-3-[(2R,4R,5S)-3-acetamido-5-[(2R,3S,5S)-5-[(2R,4R,5S)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-carboxy-3,4-dihydroxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(4-formylbenzoyl)amino]ethoxy]-4,5-dihydroxyoxane-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3S,5S,6R)-3-[(2R,4R,5S)-3-acetamido-5-[(2R,3S,5S)-5-[(2R,4R,5S)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-carboxy-3,4-dihydroxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(4-formylbenzoyl)amino]ethoxy]-4,5-dihydroxyoxane-2-carboxylic acid
• 化学式: C₃₈H₅₃N₃O₂₅
• 分子量: 951.8
• InChiKey: VCQFPVOICBTWBV-KMFOZARTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7.6
• 重原子数：
  66
• 可旋转键数：
  18
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  435
• 氢给体数：
  14
• 氢受体数：
  25

文献信息

• US9370583B2
  申请人：——

  公开号：US9370583B2

  公开（公告）日：2016-06-21
• [EN] THROMBIN SENSITIVE COAGULATION FACTOR X MOLECULES<br/>[FR] MOLÉCULES DE FACTEUR DE COAGULATION X SENSIBLE À LA THROMBINE
  申请人：NOVO NORDISK AS

  公开号：WO2014140103A2

  公开（公告）日：2014-09-18

  The present invention relates to thrombin sensitive coagulation Factor X (FX), as well as use thereof in medicine. In particular the invention relates to FX molecules comprising 2 to 10 amino acid modifications in the activation peptide N-terminally of the FX "IVGG" motif as well as compositions comprising such molecules and use thereof. Such molecules may be useful in connection with convenient and patient friendly treatment regimens in treatment and prophylaxis of haemophilia.
• [EN] COAGULATION FACTOR VII POLYPEPTIDES<br/>[FR] POLYPEPTIDES DU FACTEUR VII DE LA COAGULATION
  申请人：NOVO NORDISK HEALTHCARE AG

  公开号：WO2015055692A1

  公开（公告）日：2015-04-23

  The present invention relates to modified human coagulation Factor VII polypeptides having coagulant activity, especially variants having higher proteolytic activity and reduced antithrombin reactivity (increased resistance to inactivation by anti-thrombin) when activated as compared to wild-type FVIIa. The variants have certain substitutions at position T293 of mature human FVII in combination with specifc substitutions at L288, W201 and/or K337. The claims are also directed to pharmaceutical compositions, and medical uses of said factor VII polypeptides.
• [EN] COAGULATION FACTOR IX CONJUGATES<br/>[FR] CONJUGUÉS DU FACTEUR IX DE COAGULATION
  申请人：NOVO NORDISK HEALTHCARE AG

  公开号：WO2015121387A1

  公开（公告）日：2015-08-20

  The present invention relates to Factor IX polypeptides conjugated to heparosan (HEP) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used - for example - in the treatment or prevention of bleeding disorders such as haemophilia B.